RedFlag Index™ · #4 of 10 · NYSE: MCK

McKesson Corporation: enforcement record and regulatory exposure

McKesson Corporation scores 67 out of 100 on the RedFlag Index™ (November 2026), ranking #4 of ten tracked companies, with 3 documented cases of which 1 remain open.

McKesson's opioid-related penalties total about $8.7 billion.

2022: McKesson agreed to pay up to $7.4 billion over 18 years in the national opioid distributor settlement.

2022: RxPak, a McKesson subsidiary, paid $1 million over more than 700 alleged controlled-substance record-keeping violations.

2017: McKesson paid $150 million, then a record for a distributor, for Controlled Substances Act violations. Controlled-substance shipments from four McKesson distribution centers were suspended.

McKesson's Colorado distribution center processed more than 1.6 million controlled-substance orders from 2008 to 2013 and reported only 16 as suspicious.

2008: McKesson paid $13.25 million for Controlled Substances Act violations.

DateMatterAmountStatus
March 14, 2022RxPak controlled-substance recordkeeping settlement$1mResolved
February 2022National opioid distributor settlement (up to $7.4bn over 18 years)$7.4bnResolved, order in force
January 2017DEA/DOJ suspicious-order settlement and distribution-centre suspensions$150mResolved
May 2008DEA suspicious-order settlement$13.3mResolved

Government enforcement only. Greyed rows are more than ten years old and excluded from scoring under the temporal decay rule.

  1. Opioid Litigation

    McKesson is paying up to $7.4 billion over opioid distribution, and admits nothing.

    The largest distributor's share of the national settlement runs for 18 years. None of it goes to individual patients.

  2. Controlled Substances Act

    McKesson reported 16 suspicious orders out of 1.6 million. The penalty was $150 million.

    It was the company's second settlement for the same failure. The first, in 2008, had required it to build a monitoring system.